Boston Scien Cp - BSX STOCK NEWS

Boston Scientific (NYSE: BSX) announced that CFO Dan Brennan will retire after nearly 30 years with the company. Brennan will step down as CFO at the end of June 2025 and remain as senior advisor through early October 2025.

Jon Monson, currently senior vice president of Investor Relations, will succeed Brennan as executive vice president and CFO effective June 30, 2025. Monson brings over 25 years of experience at Boston Scientific and will oversee global controllership, internal audit, corporate finance, treasury, corporate tax, investor relations and corporate business development.

Monson previously served as global controller and chief accounting officer for five years and vice president and controller of the company's Urology business for four years. He played a key role in navigating the company through the 2020 pandemic as global controller.

Boston Scientific (NYSE: BSX) reported strong Q1 2025 financial results with net sales of $4.663 billion, marking a 20.9% reported growth and 18.2% organic growth year-over-year. The company achieved GAAP EPS of $0.45 and adjusted EPS of $0.75, surpassing guidance.

Key segment performance showed remarkable growth, with Cardiovascular segment up 26.2% and MedSurg up 11.7%. Regional performance was led by the U.S. with 31.1% growth. The company completed strategic acquisitions including Bolt Medical and announced plans to acquire SoniVie

Looking ahead, Boston Scientific projects full-year 2025 net sales growth of 15-17% on a reported basis and 12-14% organically, with adjusted EPS guidance of $2.87-2.94. For Q2 2025, the company expects reported sales growth of 17.5-19.5% and organic growth of 13-15%.

Nalu Medical has appointed Raymond W. Cohen as chairman of its board of directors. Cohen previously served as CEO and board member of Axonics, a medical device company he co-founded in 2013 and took public in 2018. Under his leadership, Axonics achieved recognition as the fastest-growing company in the Americas by Deloitte and Financial Times in 2021 and 2022.

Cohen recently oversaw Axonics' $3.7 billion sale to Boston Scientific (NYSE: BSX) in November 2024. He also served as chairman of SoniVie, which was sold to BSX for $600 million in March 2025. Currently, he serves on the board of Kestra Medical Technologies (Nasdaq: KMTS), which recently completed a $232 million IPO.

Boston Scientific (NYSE: BSX) has scheduled a conference call to discuss its first quarter 2025 financial results and business highlights on Wednesday, April 23, 2025, at 8:00 a.m. ET. The company will release its Q1 financial results prior to the call on the same day.

The conference call will be led by Mike Mahoney, chairman and CEO, alongside Dan Brennan, executive vice president and CFO. Investors and interested parties can access the live webcast and replay through the company's investor relations website.

Boston Scientific (NYSE: BSX) has announced an agreement to acquire SoniVie , developer of the investigational TIVUS™ Intravascular Ultrasound System for treating hypertension through renal denervation (RDN). The acquisition expands BSX's Interventional Cardiology Therapies portfolio.

The transaction includes an upfront payment of approximately $360 million for the 90% stake not currently owned by BSX (which holds ~10% equity), plus up to $180 million in regulatory milestone payments. The TIVUS system uses ultrasound energy to denervate renal arteries, potentially offering deeper tissue penetration and faster procedures compared to radiofrequency alternatives.

The deal is expected to close in first half 2025, with slight dilution to adjusted EPS in 2025, which BSX plans to offset through internal cost efficiencies. SoniVie recently reported positive efficacy data from an IDE pilot trial and has initiated the THRIVE global IDE pivotal trial.

Boston Scientific (NYSE: BSX) announced that its wholly owned finance subsidiary, American Medical Systems Europe B.V., has completed a public offering of €1.5 billion in senior notes. The offering consists of €850 million in 3.000% notes due 2031 and €650 million in 3.250% notes due 2034.

The notes, fully guaranteed by Boston Scientific, will be listed on the Euronext Dublin Global Exchange Market. The proceeds will be used to repay AMS Europe's 0.750% senior notes maturing March 8, 2025, pay accrued interest, and support general corporate purposes, including short-term investments, debt reduction, working capital, and potential acquisitions.

Boston Scientific (NYSE: BSX) announced that its wholly owned finance subsidiary, American Medical Systems Europe B.V., has priced a public offering of €1.5 billion in senior notes. The offering consists of €850 million in 3.000% notes due 2031 and €650 million in 3.250% notes due 2034.

The notes, fully guaranteed by Boston Scientific, are expected to close on February 26, 2025. The company plans to use the proceeds, along with cash on hand, to repay AMS Europe's 0.750% senior notes maturing March 8, 2025, pay accrued interest, and support general corporate purposes including short-term investments, debt reduction, working capital, and potential future acquisitions.

Boston Scientific (NYSE: BSX) has announced its participation in TD Cowen's 45th Annual Health Care Conference scheduled for March 4, 2025. The company will be represented by three key executives: Dan Brennan (Executive VP and CFO), Art Butcher (Executive VP and Group President, MedSurg and Asia Pacific), and Dr. Kenneth Stein (Senior VP and Chief Medical Officer).

The executives will engage in a 30-minute fireside chat with the host analyst, beginning at approximately 9:10 a.m. ET. The session will be available via live webcast, with a replay accessible on the company's investor relations website approximately one hour after the event concludes.

Boston Scientific (BSX) reported strong financial results for Q4 and full year 2024. Q4 net sales reached $4.561 billion, growing 22.4% on a reported basis, with GAAP EPS of $0.38 and adjusted EPS of $0.70. Full-year 2024 net sales were $16.747 billion, up 17.6%, with GAAP EPS of $1.25 and adjusted EPS of $2.51.

The company showed significant growth across segments, with Cardiovascular growing 28.8% and MedSurg up 12.4% in Q4. Regional performance was led by the U.S. with 30.7% growth. Notable developments include positive clinical trial results for WATCHMAN FLX™ and FARAPULSE™ systems, plus strategic acquisitions of Axonics and Cortex.

For 2025, BSX projects full-year net sales growth of 12.5-14.5% on a reported basis and adjusted EPS of $2.80-$2.87. Q1 2025 guidance indicates 17-19% reported sales growth with adjusted EPS of $0.66-$0.68.